

1 Research Article

2 **Metabolic signature of a functional high-catechin tea after acute and sustained**
3 **consumption in healthy volunteers through 1H NMR-based metabolomic analysis**
4 **of urine**

5 Francisco Madrid-Gambin,^{†,||} Mar Garcia-Aloy,^{†,||} Rosa Vázquez-Fresno,[†] Esteban
6 Vegas-Lozano,[§] Alex Sánchez-Pla,[§] Koichi Misawa,[‡] Tadashi Hase,[‡] Akira
7 Shimotoyodome,[‡] Cristina Andres-Lacueva^{*,†,||}

8

9 [†]Biomarkers & Nutrimetabolomics Laboratory, Department of Nutrition, Food Sciences
10 and Gastronomy, Food Technology Reference Net (XaRTA), Nutrition and Food Safety
11 Research Institute (INSA), Campus Torribera, Faculty of Pharmacy and Food Sciences,
12 University of Barcelona, Barcelona, Spain

13 ^{||}CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos
14 III, Barcelona, Spain

15 [§]Department of Statistics, University of Barcelona, Barcelona, Spain

16 [‡]Biological Science Laboratories, Kao Corporation, 2606, Akabane, Ichikai, Haga,
17 Tochigi, 321-3497, Japan

18 *Correspondence: Cristina Andres-Lacueva (candres@ub.edu). Tel: +34.934034840.

19 Fax: +34.934035931.

20 **ABSTRACT**

21 Functional tea beverages have emerged as a novel approach to achieve health benefits
22 associated with tea. The use of metabolomics may improve the evaluation of their
23 consumption and their effects beyond self-reported questionnaires. The current study
24 aimed to explore the urinary signature of the exposure to a functional high-catechin tea
25 (HCT) using an untargeted NMR-based metabolomics approach. Ten male volunteers
26 participated in a dietary crossover randomized intervention study. Individuals consumed
27 a HCT or a control beverage during 28 days. Multilevel partial least squares
28 discriminant analysis (ML-PLS-DA) was used for paired comparisons across the
29 crossover design. A further univariant crossover-model was performed to assess the
30 significant changes. The acute intake of HCT resulted in the excretion of theanine,
31 gallate, epicatechin and epigallocatechin, as well as higher levels of 3-methyl-2-
32 oxovalerate. The sustained consumption of the HCT exhibited the excretion of
33 pyrogallol, higher succinate levels and a lower excretion of 2-hydroxyisobutyrate. After
34 the repeated exposure to HCT, the acute intake of HCT exhibited a new performance of
35 food metabolome compounds mentioned above. In conclusion, the present work settled
36 known regular tea biomarkers, and novel urinary signatures. Such signatures may be
37 potential biomarkers and/or reflect certain benefits of functional tea beverages.

38

39 **KEYWORDS**

40 tea; catechins; theanine; metabolomics; NMR; biomarkers

41 INTRODUCTION

42 Tea (*Camellia sinensis*) is a common beverage with high consumption per capita
43 worldwide.¹ The chemical composition of tea is affected by the fermentation process.
44 The different types of tea are classified into green and white tea (unfermented), oolong
45 tea (semi-fermented), black tea (fully fermented) and pu-erh tea (post-fermented).^{2,3}
46 Green tea is rich in several catechins (flavan-3-ols), being the most abundant
47 polyphenols in this beverage, whereas, theaflavins and thearubigins are abundant in
48 black tea.⁴ Furthermore, epigallocatechin gallate (EGCG) is the most important catechin
49 in green tea but also other catechins and their epimeric forms are found such as
50 epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC), catechin (C),
51 galocatechin (GC), catechin gallate (CG), and galocatechin gallate (GCG).⁵
52 Advances in ready-to-drink teas have been developed to innovate with brewing
53 requirements of premium leaf while responding as a suitable way for fortification that
54 can add more health benefits to these functional drinks.^{6,7} In addition, there is an
55 increasing use of polyphenols and functional beverages due to the high demands for
56 polyphenol-rich consumables.⁸ There are numerous studies concerning its benefits for
57 health^{9,10} finding that most of the observed health-effects are attributed to its
58 polyphenols.¹¹ Concretely, the U.S. Food and Drug Administration approved the health
59 claims for green tea consumption against risk of breast and prostate cancers.¹² There are
60 also several studies relating tea consumption with benefits on other chronic diseases,
61 such as cardiovascular, metabolic and neurodegenerative diseases, but showing lack of
62 consistency in the levels commonly consumed by human populations.¹³ The traditional
63 methods to determine the consumption are based on the use of food frequency
64 questionnaires.¹⁴ Regular tea intake is usually measured in the number of cups of tea
65 consumed per day⁴ whereby this methodology may provide unpredictability to

66 epidemiologic studies. Several biomarkers of tea intake have been proposed using mass
67 spectrometry.¹⁵ In acute intervention studies with green tea, EC, EGC and conjugated
68 metabolites are predominant in short-term urine samples.^{16,17} Longer exposures to green
69 tea showed the presence of microbial co-metabolites such as certain valerolactones in
70 24-h urine samples.^{18,19} These metabolites were associated with tea in cross-sectional
71 studies.^{20,21} A lower number of studies described 1,3-dihydroxyphenyl-2-O-sulfate
72 (pyrogallol sulfate), hippuric acid, 4-hydroxyhippuric acid and gallic acid²²⁻²⁴ as main
73 tea biomarkers using ¹H-NMR-based metabolomics. Nevertheless, these metabolites are
74 not highly specific for tea since they were found after other food sources such as coffee,
75 cocoa, wine, fruits or vegetables.²⁵⁻²⁸ The application of metabolomics in the nutrition
76 field may let to discover accurate biomarkers of intake and also may reveal potential
77 modifications in diet-related pathways in healthy individuals likewise in early disease
78 stages.^{14,29} Metabolomics allows a global description of metabolites that gives detailed
79 information on metabolic pathways and in turn on biological processes, thereby
80 clarifying associations with health benefits and elucidating underlying mechanisms.³⁰
81 More concretely, while the biomarkers of intake reflect the dietary exposure, altered
82 endogenous compounds may reveal the mechanistic role of functional foods.³¹
83 Therefore, the present study was conducted to determine the metabolic fingerprint of a
84 functional green tea high in catechin polyphenols on the urinary metabolome after both
85 acute and sustained consumptions.

86 **MATERIALS AND METHODS**

87 **Subjects and study design**

88 Ten healthy male volunteers between 25 and 44 years old with a body mass index
89 (BMI) of 23.0±2.0 kg/m² (mean ± SD) participated in a randomized, double-blind,

90 placebo-controlled, crossover clinical trial (Figure 1). Exclusion criteria included
91 caffeine intoxication, intake of catechins supplements, serious illness (such as heart
92 disease, kidney disease or diabetes) and food allergies. The study protocol was
93 approved by the Human Research Ethics Committee of Biological Science Laboratories
94 of the KAO Corporation (ref: 507-20131218). This clinical trial was registered with the
95 International Standard Randomized Controlled Trial Number (ISRCTN) 15516017.

96 During the washout and the study periods, the subjects were forbidden to consume
97 coffee and tea beverages other than test drinks. Subjects were not allowed to consume
98 alcoholic beverages and to practice exercise from 2 days before the beginning of the
99 intervention. After a 14-day washout period, subjects were asked to consume a
100 functional high-catechins tea beverage (hereafter HCT) containing 187 mg/100 ml of
101 catechins (KAO Corporation, Japan) or a control beverage (caffeine-containing
102 beverage). The daily dose of caffeine was similar between the intervention and control
103 groups (see Table S1, Supporting Information). Then, the participants consumed the
104 corresponding beverage every day for the next 28 days (period I). The same procedure
105 was repeated switching the individuals between the groups (period II) after a second 14-
106 day washout period, in accordance with the crossover design. To analyse acute
107 consumption, urine samples collected during the first 4 postprandial hours after intake
108 were obtained on the first day of the intervention. Fasting urine samples were collected
109 on the first and last days of each period for the analysis of sustained consumption.

110 Finally, in order to analyse the repeated exposures reflecting the habitual intakes to this
111 drink, urine samples collected during the first 4 postprandial hours after intake were
112 collected during the final day of each period. All urine samples were stored in aliquots
113 at $-80\text{ }^{\circ}\text{C}$ prior to analysis.

114

115 **Sample preparation and data acquisition**

116 Sample processing and data acquisition were performed as previously described.²⁷ Both
117 urine and beverage samples were thawed, vortexed and centrifuged at 13,200 rpm for 5
118 min. The supernatant (600 μ L) from each sample was mixed with an internal standard
119 solution [120 μ L, consisting of 0.1% TSP (3-(trimethylsilyl)-propionate-2,2,3,3-d₄,
120 chemical shift reference), 2 mM of sodium azide (NaN₃, bacteriostatic agent) and 1.5 M
121 KH₂PO₄ in 99% deuterium water (D₂O)]. The optimized pH of the buffer was set at 7.0,
122 with a potassium deuterioxide (KOD) solution, to minimize variations in the chemical
123 shifts of the NMR resonances. This mixture was transferred to a 5 mm NMR tube.

124 Urinary spectra were acquired on a Varian-Inova-500 MHz NMR spectrometer with
125 presaturation of the water resonance using a NOESYPRESAT pulse sequence. During
126 the acquisition, the internal temperature was kept constant at 298 K. An exponential
127 window function was applied to the free induction decay (FID) with a line-broadening
128 factor of 0.3 Hz prior to the Fourier transformation. For each sample, a total of 128
129 scans were recorded into 32 K data points with a spectral width of 14 ppm, an
130 acquisition time of 2 s and a relaxation delay of 5 s. HCT spectra were acquired on a
131 Bruker Avance III 400 MHz NMR spectrometer equipped with a cryoprobe with
132 presaturation of the water resonance using a NOESYPRESAT pulse sequence. The
133 internal temperature was kept constant at 298 K and the sample was processed with a
134 line-broadening factor of 0.3 Hz, 64 scans with a spectral width of 15 ppm, an
135 acquisition time of 3 s and a relaxation delay of 5 s.

136 Spectra were manually phased, baseline corrected and calibrated (TSP, 0.0 ppm) using
137 TopSpin software (version 3.0, Bruker, BioSpin, Germany). Spectra data were bucketed
138 in intelligent bucketing domains of 0.005 ppm with ACD/NMR Processor 12.0 software

139 (Advanced Chemistry Development, Toronto, Canada). The water signal and the noise
140 regions above 9.5 ppm and below 0.5 ppm were excluded from the analysis.

141 **Data processing and statistical analysis**

142 Data from (i) acute intervention, (ii) sustained intervention and (iii) acute intervention
143 after the repeated exposure were submitted separately to MetaboAnalyst 3.0 for
144 normalization purposes.³² Data were row-wise normalized by the sum of the intensities
145 of the spectra and column-wise normalized using cube root transformation and Pareto
146 scaling.

147 Datasets were then imported to R software version 3.1.2.³³ Principal component
148 analysis (PCA) was performed on baseline samples to acquire an overview of
149 individuals and to detect potential carryover effects. After performing the differences
150 between baseline and intervention data of each volunteer (Δ data), multilevel partial
151 least squares discriminant analysis (ML-PLS-DA)³⁴ was used on Δ data for paired
152 comparisons of HCT versus control beverage using the ‘mixOmics’ R-package.³⁵ The
153 “leave-one-subject-out” cross-validation was used to assess the models and the
154 classification error rate was calculated by comparing the actual class with the predicted
155 one. Significant variables were obtained based on the lowest classification error rate and
156 on loading scores from the first latent variable.²⁷ Absolute values of loading scores were
157 ranked and the top 5% of total features were selected as long as those variables were
158 kept at the lowest classification error rate. These features were employed to model a
159 sparse ML-PLS-DA. Signals from the sparse ML-PLS-DA were ranked based on the
160 absolute values of their loading scores termed loading rank, LR.²⁷

161 The univariate crossover model^{36,37} of Δ data was also performed between groups to
162 assess the statistical significances. In addition to individual effect, the period (I and II)
163 and the sequence (from control to test interventions, or from test to control

164 interventions) followed by each volunteer were considered in the crossover model for
165 further correction on carryover effects. Statistical significance was considered at a *p*-
166 *value* <0.05.

167 **Metabolite identification**

168 Metabolite identification were performed using Chenomx NMR Suite Professional
169 Software package (version 8.1; Chenomx Inc, Edmonton, Canada) and by comparing
170 NMR spectral data to those available in databases such as the Human Metabolome
171 Database (<http://www.hmdb.ca>), along with the existing NMR-based metabolomics
172 literature. Further, a Pearson's correlation test was performed to assess correlations
173 between signals of the same metabolite.

174 **RESULTS AND DISCUSSION**

175 **¹H NMR profiling of the HCT**

176 Metabolic profiling of the HCT beverage was carried out for further exploration of the
177 urinary signatures coming from the functional beverage. The identified compounds with
178 the corresponding chemical shifts are summarized in Table S2. Several compounds
179 naturally present in tea, susceptible to be found in urine, were identified in the HCT.
180 EC, EGCG and EGC are frequently reported in regular green tea beverages although in
181 lower concentrations (Table S3).³⁸ The characteristic signals corresponding to gallate
182 and theanine, which were previously described in tea beverages,^{3,39} were observed on
183 the HCT spectra and subsequently found in the urine in the present study (see below).
184 Other compounds such as caffeine, theobromine, catechol and quinate were also
185 identified in the HCT as previous described in regular tea.³⁹

186

187 **Assessment of multi- and univariate approaches**

188 PCA did not indicate the presence of carryover effects (Figure S1). There was no sign
189 difference between the control group and the HCT group on baseline samples in terms of
190 period and sequence. The differences between the control group and the HCT group
191 resulted in three ML-PLS-DA models on the Δ data, with a minimum classification error
192 rate of 0.1 for the sustained intervention and 0.0 for both the first acute study and the
193 second acute study after the sustained treatment. The lowest estimated classification error
194 rate remained for a range between the 2nd and the 39th variable after the first acute
195 intervention, whereas in the sustained intervention the minimum estimated classification
196 rate was from the 7th to the 10th variable. For the second acute study after the prolonged
197 HCT consumption, the classification error rate was kept to 0.0 during the first 93 variables.
198 Hence, three sparse ML-PLS-DA models were constructed with the selected variables.
199 Discriminant features projected in the first component were ranked according the loading
200 score values and set in the LRs.

201 The statistical univariate crossover models revealed that a total of 8 compounds were
202 significantly different between HCT and control beverages. As expected, there was a
203 strong agreement between uni- and multivariate analyses performed separately, in
204 which lowest *p*-values matched with the highest loading scores, and thus, lowest
205 loading rank, as it is shown in Table 1. Figure 2 shows box plots of the metabolites
206 levels for HCT and control groups.

207 **Urinary compounds from the food metabolome**

208 After the punctual intake (single dose) of HCT, several compounds coming from the
209 beverage were found in the 4h-urine. A prominent signal at δ 2.04 and a triplet at δ 1.12
210 were originally assigned to theanine (Table 1). Then, a triplet at δ 3.79 and a multiplet at
211 δ 3.18 were also correlated between the signals corroborating the identification.
212 Theanine is a nonproteinogenic amino acid present in green tea⁴⁰ and the mushrooms

213 *Xerocomus badius*⁴¹ that improves memory and attention.⁴² Interestingly, this
214 compound was also identified in the HCT used in the study (Table S2). Therefore
215 theanine may display a possible direct excretion from tea (Figure 3). Van der Pijl and
216 co-workers found maximum plasmatic concentrations of theanine after 50 min of the
217 intake of 25, 50, and 200 mg L-theanine provided via an aqueous solution or black tea.⁴³
218 Similar results were observed by Scheid and co-workers finding a maximum plasma
219 concentration of theanine at 0.8 h after capsules and green tea intake; also found in the
220 urine of participants collected within the interval 3-24 h after intake.⁴⁴ In consonance
221 with these findings, we identified theanine in urine sample collected within the first 4 h,
222 entailing an early excretion of this potential biomarker. Gallate and EC were also
223 detected in 4h-urine and also the HCT beverage (Figure 3) denoting the successful
224 absorption and excretion of those compounds as suggested by Rhodes and co-authors.⁴⁵
225 Nevertheless, although the methylated, glucuronide and sulfate catechins forms are
226 frequently detected by mass spectrometry,^{19,46,47} they were not detected in the present
227 study. EGC was weakly detected in urine in spite of being strongly distinguished
228 through the singlet δ 6.59 in the beverage. In contrast, urinary EGC was firmly detected
229 by other authors using liquid chromatography.^{16,17,21} Interestingly, ECG and EGCG,
230 which were identified in the HCT beverage, were not detected in the urine of
231 participants. While Del Rio et al., (2010) and Stalmach et al., (2009) described the
232 presence of unmetabolized EGCG and ECG in plasma after tea ingestion, neither EGCG
233 nor ECG were easily detected in the urinary metabolome.^{19,48,49} This fact implicates that
234 the unmetabolized forms of EGCG and ECG probably are not suitable urinary
235 biomarkers of tea intake. We tentatively assigned pyrogallol (sulfate) to the doublet
236 shown at δ 6.59 and signals at δ 7.05 based on the previous work of the authors Daykin,
237 2005; and Van Dorsten, 2006.^{22,23} This metabolite is derived from the cleavage of the 3-

238 O-gallate groups.⁵⁸ These authors also suggested other metabolites such as hippuric acid
239 as major urinary metabolite; however, this was not observed in our study. Pyrogallol
240 (sulfate) was significant according the crossover model (Table 1). Nevertheless, the
241 statistical power of the multivariate approach was not strong due to the presence of this
242 metabolite only in certain individuals. This inter-individual variation in the excretion
243 may be related to the colonic microbiota response of participants.⁵⁹ Therefore, the
244 variability in the biological effects of tea consumption are related to the presence or the
245 absence of certain microorganisms and their metabolites in the gut.⁶⁰ Lastly, the
246 punctual intake of the beverage after a prolonged exposure seated the findings of the
247 first acute intake, replicating short-terms biomarkers of intake such as theanine, EC and
248 gallate. However, in the fasted urine collected after the sustained exposure, none of
249 these compounds were found to be statistically significant in any participant entailing
250 the return to baseline levels within the 24 h after the last intake. In fact, most excretions
251 of the flavan-3-ol metabolites occur within the first 12 h after intake.⁵⁰ Therefore, as we
252 expected, these metabolites were newly observed in 4h-urine after a new intake.
253 Overall, the present findings confirm known intake biomarkers coming from the food
254 metabolome, but also propose new potential compounds that should be further studied
255 as novel biomarkers of intake.

256 **Endogenous and microbial metabolites**

257 Regarding endogenous compounds, mainly metabolites from tricarboxylic acid (TCA)
258 cycle and microbiota activity were altered. After the intake of the HCT, 3-methyl-2-
259 oxovalerate, which is a product of isoleucine metabolism, was statistically increased in
260 4h-urine after both punctual and prolonged consumption. Isoleucine is metabolized to
261 succinate via the methylmalonyl-CoA⁵¹ in TCA cycle. Urinary succinate was also raised
262 after prolonged consumption in both 4h- and 24h-urine samples. Similar studies giving

263 a single dose of a rich-polyphenol food such as coffee and wine exhibited higher urinary
264 levels of 3-methyl-2-oxovalerate and succinate.^{27,52} The branched-chain keto-acid 3-
265 methyl-2-oxovalerate was also the strongest predictive biomarker for type 2 diabetes
266 and impaired fasting glucose,⁵³ while succinate was found to be increased after the
267 consumption of regular green tea and green tea with ascorbate in rats.⁵⁴ The fact that
268 nutritional studies included healthy volunteers may point to a strong impact on energy
269 regulation by polyphenols even in short-term,⁵⁵ especially observed in tea.^{56,57}
270 Therefore, the increased levels of 3-methyl-2-oxovalerate and succinate reflect this
271 regulation by the functional tea rather than an illness situation in the present study. After
272 the sustained consumption of HCT, several compounds were related to microbiota
273 metabolism of catechins. The crossover model revealed a decrease of the singlet δ 1.36
274 in the HCT group, identified as 2-hydroxyisobutyrate. Li and co-workers used
275 combination of spectroscopic, microbiomic, and multivariate statistical tools to model
276 the microbial–host connections and showed this compound associated to the presence of
277 *Faecalibacterium prausnitzii* in the colon.⁶¹ This metabolite was associated to the
278 microbial degradation of undigested proteins in the gastrointestinal tract.⁶¹ The
279 compound was also reported as discriminant between obese and lean individuals
280 demonstrating functional differences in the microbiome metabolic activity.⁶² The
281 urinary metabotype of obese individuals was characterized by a higher concentration of
282 2-hydroxyisobutyrate and lower levels of hippuric acid, trigonelline and xanthine. In
283 this sense, lower excretion of 2-hydroxyisobutyrate may be associated to a gut
284 microbiota modulation by the constituents present in the functional green tea and might
285 be the responsible of certain health benefits in terms of obesity and Crohn disease.⁶³ In
286 summary, the present endogenous metabolites might be connected with certain benefits
287 derived of functional beverages.

288 Our study shows evidence for metabolic changes by a functional beverage composed by
289 higher concentrations of catechins than a regular green tea. Unlike the expected results,
290 theanine was a prominent urinary biomarker, beyond the catechins present as food
291 metabolome compounds from the functional beverage. The HCT also had an impact on
292 the endogenous metabolome. Certain metabolites connected to TCA cycle and to the
293 microbial activity were found to be altered in urine suggesting some of the connections
294 to the described health benefits by tea. In conclusion, we not only seated the presence of
295 tea markers but also present metabolic changes based on endogenous alterations.
296 theanine as intake biomarker as well as different biomarkers of effect.

297 **ABBREVIATIONS**

298 BMI, body mass index; C, catechin; CG, catechin gallate; EC, epicatechin; ECG,
299 epicatechin gallate; EGC, epigallocatechin; EGCG, epigallocatechin gallate; GC,
300 galocatechin; GCG galocatechin gallate; HCT, high catechin tea; FID, free induction
301 decay; ISRCTN, International Standard Randomized Controlled Trial Number; KOD,
302 potassium deuterioxide; LR, loading rank; ML-PLS-DA, multilevel partial least squares
303 discriminant analysis; NMR, Nuclear Magnetic Resonance; PCA, Principal component
304 analysis; TCA, tricarboxylic acid; TSP, (3-(trimethylsilyl)-proprionate-2,2,3,3-d₄).

305 **FUNDING SOURCES**

306 This research was funded by The Fondo Europeo de Desarrollo Regional (FEDER) and
307 the JPI HDHL FOOTBALL (PCIN-2014-133-MINECO-Spain). The clinical study was
308 supported in part by the KAO Corporation and Fundació Bosch i Gimpera (FBG
309 307683). We also thank the award of 2017SGR1546 from the Generalitat de
310 Catalunya's Agency AGAUR.

311 **AUTHOR CONTRIBUTIONS**

312 The authors' responsibilities were as follows — F.M-G: wrote the manuscript; F.M-G,
313 E.V-L and A.S-P: design and conducted the statistical analysis; F.M-G, M.G-A, and
314 R.V-F: conducted the research; F.M-G and R.V-F: performed the samples analyses;
315 F.M-G, M.G-A, E.V-L, A.S-P, K.M., T.H., A.S and CA-L: provided critical revision of
316 the manuscript; K.M., T.H., and A.S. designed and conducted the intervention study,
317 CA-L: had primary responsibility for the final content of the manuscript; and all
318 authors: read and approved the final manuscript.

319 The authors report no financial interests or potential conflicts of interest.

320 **SUPPORTING INFORMATION**

321 Table S1. Composition of beverages used in the study. Table S2. Compounds identified
322 in the HCT beverage by NMR spectroscopy. Table S3. Composition of catechins of the
323 HCT used in the study and the reported composition in regular green tea. Figure S1.
324 Principal component analysis (PCA) of baseline points in control and HCT groups in
325 both I and II periods of the crossover study.

326 **REFERENCES**

- 327 (1) Holick, C. N.; Smith, S. G.; Giovannucci, E.; Michaud, D. S. Coffee, tea,
328 caffeine intake, and risk of adult glioma in three prospective cohort studies.
329 *Cancer Epidemiol. Biomarkers Prev.* **2010**, *19* (1), 39–47.
- 330 (2) Zuo, Y. Simultaneous determination of catechins, caffeine and gallic acids in
331 green, Oolong, black and pu-erh teas using HPLC with a photodiode array
332 detector. *Talanta* **2002**, *57* (2), 307–316.
- 333 (3) Horanni, R.; Engelhardt, U. H. Determination of amino acids in white, green,
334 black, oolong, pu-erh teas and tea products. *J. Food Compos. Anal.* **2013**, *31* (1),
335 94–100.
- 336 (4) Sang, S.; Lambert, J. D.; Ho, C.-T.; Yang, C. S. The chemistry and
337 biotransformation of tea constituents. *Pharmacol. Res.* **2011**, *64* (2), 87–99.
- 338 (5) Ferruzzi, M. G. The influence of beverage composition on delivery of phenolic
339 compounds from coffee and tea. *Physiol. Behav.* **2010**, *100* (1), 33–41.
- 340 (6) Ansari, M. M.; Kumar, D. S. Fortification of Food and Beverages with
341 Phytonutrients. *Food Public Heal.* **2012**, *2* (6), 241–253.
- 342 (7) Puiggròs, F.; Muguerza, B.; Arola-Arnal, A.; Aragonès, G.; Suárez-Garcia, S.;
343 Bladé, C.; Arola, L.; Suárez, M. Functional Beverages. In *Innovative*
344 *Technologies in Beverage Processing*; John Wiley & Sons, Ltd: Chichester, UK,
345 2017; pp 275–296.
- 346 (8) Adebooye, O. C.; Alashi, A. M.; Aluko, R. E. A brief review on emerging trends
347 in global polyphenol research. *J. Food Biochem.* **2018**, e12519.
- 348 (9) Chen, L.; Mo, H.; Zhao, L.; Gao, W.; Wang, S.; Cromie, M. M.; Lu, C.; Wang,
349 J.-S.; Shen, C.-L. Therapeutic properties of green tea against environmental
350 insults. *J. Nutr. Biochem.* **2017**, *40*, 1–13.

- 351 (10) Chen, Z.; Lin, Z. Tea and human health: biomedical functions of tea active
352 components and current issues. *J. Zhejiang Univ. Sci. B* **2015**, *16* (2), 87–102.
- 353 (11) Matsui, T. Condensed catechins and their potential health-benefits. *Eur. J.*
354 *Pharmacol.* **2015**, *765*, 495–502.
- 355 (12) US Food & Drugs Administration. Letter Updating the Green Tea and Risk of
356 Breast Cancer and Prostate Cancer Health Claim April 17, 2012. *USFDA* **2012**,
357 *April 17*.
- 358 (13) Yang, C. S.; Hong, J. Prevention of chronic diseases by tea: possible mechanisms
359 and human relevance. *Annu. Rev. Nutr.* **2013**, *33*, 161–181.
- 360 (14) Scalbert, A.; Brennan, L.; Manach, C.; Andres-Lacueva, C.; Dragsted, L. O.;
361 Draper, J.; Rappaport, S. M.; van der Hoof, J. J.; Wishart, D. S. The food
362 metabolome: a window over dietary exposure. *Am. J. Clin. Nutr.* **2014**, *99* (6),
363 1286–1308.
- 364 (15) Stalmach, A.; Mullen, W.; Steiling, H.; Williamson, G.; Lean, M. E. J.; Crozier,
365 A. Absorption, metabolism, and excretion of green tea flavan-3-ols in humans
366 with an ileostomy. *Mol. Nutr. Food Res.* **2010**, *54* (3), 323–334.
- 367 (16) Henning, S. M.; Wang, P.; Said, J. W.; Huang, M.; Grogan, T.; Elashoff, D.;
368 Carpenter, C. L.; Heber, D.; Aronson, W. J. Randomized clinical trial of brewed
369 green and black tea in men with prostate cancer prior to prostatectomy. *Prostate*
370 **2015**, *75* (5), 550–559.
- 371 (17) Wang, P.; Aronson, W. J.; Huang, M.; Zhang, Y.; Lee, R.-P.; Heber, D.;
372 Henning, S. M. Green tea polyphenols and metabolites in prostatectomy tissue:
373 implications for cancer prevention. *Cancer Prev. Res. (Phila)*. **2010**, *3* (8), 985–
374 993.
- 375 (18) Henning, S. M.; Wang, P.; Abgaryan, N.; Vicinanza, R.; Moura De Oliveira, D.;

- 376 Zhang, Y.; Lee, R.-P.; Carpenter, C. L.; Aronson, W. J.; Heber, D. Phenolic acid
377 concentrations in plasma and urine from men consuming green or black tea and
378 potential chemopreventive properties for colon cancer. *Mol. Nutr. Food Res*
379 **2013**, *57*, 483–492.
- 380 (19) Calani, L.; Del Rio, D.; Luisa Callegari, M.; Morelli, L.; Brighenti, F. Updated
381 bioavailability and 48 h excretion profile of flavan-3-ols from green tea in
382 humans. *Int. J. Food Sci. Nutr.* **2012**, *63* (5), 513–521.
- 383 (20) Yuan, J.-M.; Gao, Y.-T.; Yang, C. S.; Yu, M. C. Urinary biomarkers of tea
384 polyphenols and risk of colorectal cancer in the Shanghai Cohort Study. *Int. J.*
385 *Cancer* **2007**, *120* (6), 1344–1350.
- 386 (21) Inoue-Choi, M.; Yuan, J.-M.; Yang, C. S.; Van Den Berg, D. J.; Lee, M.-J.; Gao,
387 Y.-T.; Yu, M. C. Genetic Association Between the COMT Genotype and Urinary
388 Levels of Tea Polyphenols and Their Metabolites among Daily Green Tea
389 Drinkers. *Int. J. Mol. Epidemiol. Genet.* **2010**, *1* (2), 114–123.
- 390 (22) Van Dorsten, F. A.; Daykin, C. A.; Mulder, T. P. J.; Van Duynhoven, J. P. M.
391 Metabonomics approach to determine metabolic differences between green tea
392 and black tea consumption. *J. Agric. Food Chem.* **2006**, *54* (18), 6929–6938.
- 393 (23) Daykin, C. A.; Van Duynhoven, J. P. M.; Groenewegen, A.; Dachtler, M.; Van
394 Amelsvoort, J. M. M.; Mulder, T. P. J. Nuclear magnetic resonance spectroscopic
395 based studies of the metabolism of black tea polyphenols in humans. *J. Agric.*
396 *Food Chem.* **2005**, *53* (5), 1428–1434.
- 397 (24) Van Velzen, E. J. J.; Westerhuis, J. A.; Van Duynhoven, J. P. M.; Van Dorsten,
398 F. A.; Grün, C. H.; Jacobs, D. M.; Duchateau, G. S. M. J. E.; Vis, D. J.; Smilde,
399 A. K. Phenotyping tea consumers by nutrikinetic analysis of polyphenolic end-
400 metabolites. *J. Proteome Res.* **2009**, *8* (7), 3317–3330.

- 401 (25) Mennen, L. I.; Sapinho, D.; Ito, H.; Bertrais, S.; Galan, P.; Hercberg, S.; Scalbert,
402 A. Urinary flavonoids and phenolic acids as biomarkers of intake for polyphenol-
403 rich foods. *Br. J. Nutr.* **2006**, *96* (1), 191–198.
- 404 (26) Krupp, D.; Doberstein, N.; Shi, L.; Remer, T. Hippuric Acid in 24-Hour Urine
405 Collections Is a Potential Biomarker for Fruit and Vegetable Consumption in
406 Healthy Children and Adolescents. *J. Nutr.* **2012**, *142* (7), 1314–1320.
- 407 (27) Madrid-Gambin, F.; Garcia-Aloy, M.; Vázquez-Fresno, R.; Vegas-Lozano, E.; de
408 Villa Jubany, M. C. R.; Misawa, K.; Hase, T.; Shimotoyodome, A.; Andres-
409 Lacueva, C. Impact of chlorogenic acids from coffee on urine metabolome in
410 healthy human subjects. *Food Res. Int.* **2016**, *89*, 1064–1070.
- 411 (28) Urpi-Sarda, M.; Monagas, M.; Khan, N.; Lamuela-Raventos, R. M.; Santos-
412 Buelga, C.; Sacanella, E.; Castell, M.; Permanyer, J.; Andres-Lacueva, C.
413 Epicatechin, procyanidins, and phenolic microbial metabolites after cocoa intake
414 in humans and rats. *Anal. Bioanal. Chem.* **2009**, *394* (6), 1545–1556.
- 415 (29) Puiggròs, F.; Canela, N.; Arola, L. Metabolome responses to physiological and
416 nutritional challenges. *Curr. Opin. Food Sci.* **2015**.
- 417 (30) Brennan, L. NMR-based metabolomics: From sample preparation to applications
418 in nutrition research. *Prog. Nucl. Magn. Reson. Spectrosc.* **2014**, *83*, 42–49.
- 419 (31) Ammar, N. M.; Farag, M. A.; Kholeif, T. E.; Metwally, N. S.; El-Sheikh, N. M.;
420 El Gendy, A. N.; Abdel- Hamid, A.-H. Z. Serum metabolomics reveals the
421 mechanistic role of functional foods and exercise for obesity management in rats.
422 *J. Pharm. Biomed. Anal.* **2017**, *142*, 91–101.
- 423 (32) Xia, J.; Sinelnikov, I. V.; Han, B.; Wishart, D. S. MetaboAnalyst 3.0—making
424 metabolomics more meaningful. *Nucleic Acids Res.* **2015**.
- 425 (33) R Core Team. R: A language and environment for statistical computing. *R*

- 426 *Foundation for Statistical Computing*. Vienna, Austria. 2015.
- 427 (34) Van Velzen, E. J. J.; Westerhuis, J. a.; Van Duynhoven, J. P. M.; Van Dorsten, F.
428 a.; Hoefsloot, H. C. J.; Jacobs, D. M.; Smit, S.; Draijer, R.; Kroner, C. I.; Smilde,
429 A. K. Multilevel data analysis of a crossover designed human nutritional
430 intervention study. *J. Proteome Res.* **2008**, 7 (10), 4483–4491.
- 431 (35) Lê Cao, K.-A.; González, I.; Déjean, S. integrOmics: an R package to unravel
432 relationships between two omics datasets. *Bioinformatics* **2009**, 25 (21), 2855–
433 2856.
- 434 (36) Senn, S. *Cross-over Trials in Clinical Research*; 2002.
- 435 (37) Jones, B.; Kenward, M. G. *Design and Analysis of Cross-Over Trials, Third*
436 *Edition*; CRC Press, 2014.
- 437 (38) Rothwell, J. A.; Urpi-Sarda, M.; Boto-Ordoñez, M.; Knox, C.; Llorach, R.;
438 Eisner, R.; Cruz, J.; Neveu, V.; Wishart, D.; Manach, C.; et al. Phenol-Explorer
439 2.0: a major update of the Phenol-Explorer database integrating data on
440 polyphenol metabolism and pharmacokinetics in humans and experimental
441 animals. *Database (Oxford)*. **2012**, 2012 (0), bas031.
- 442 (39) Yuan, Y.; Song, Y.; Jing, W.; Wang, Y.; Yang, X.; Liu, D. Simultaneous
443 determination of caffeine, gallic acid, theanine, (–)-epigallocatechin and (–)-
444 epigallocatechin-3-gallate in green tea using quantitative ¹H-NMR spectroscopy.
445 *Anal. Methods* **2014**, 6 (3), 907–914.
- 446 (40) Sakato Y. The chemical constituents of tea : III. A new amide theanine. *Nippon*
447 *Nogeikagaku Kaishi* **1949**, 23, 262–267.
- 448 (41) Casimir, J.; Jadot, J.; Renard, M. [Separation and characterization of N-ethyl-
449 gamma-glutamine from *Xerocomus badius*]. *Biochim. Biophys. Acta* **1960**, 39,
450 462–468.

- 451 (42) Park, S.-K.; Jung, I.-C.; Lee, W. K.; Lee, Y. S.; Park, H. K.; Go, H. J.; Kim, K.;
452 Lim, N. K.; Hong, J. T.; Ly, S. Y.; et al. A Combination of Green Tea Extract
453 and L-Theanine Improves Memory and Attention in Subjects with Mild
454 Cognitive Impairment: A Double-Blind Placebo-Controlled Study. *J. Med. Food*
455 **2011**, *14* (4), 334–343.
- 456 (43) van der Pijl, P. C.; Chen, L.; Mulder, T. P. J. Human disposition of L-theanine in
457 tea or aqueous solution. *J. Funct. Foods* **2010**, *2* (4), 239–244.
- 458 (44) Scheid, L.; Ellinger, S.; Altheheld, B.; Herholz, H.; Ellinger, J.; Henn, T.;
459 Helfrich, H.-P.; Stehle, P. Kinetics of L-theanine uptake and metabolism in
460 healthy participants are comparable after ingestion of L-theanine via capsules and
461 green tea. *J. Nutr.* **2012**, *142* (12), 2091–2096.
- 462 (45) Rhodes, L. E.; Darby, G.; Massey, K. A.; Clarke, K. A.; Dew, T. P.; Farrar, M.
463 D.; Bennett, S.; Watson, R. E. B.; Williamson, G.; Nicolaou, A. Oral green tea
464 catechin metabolites are incorporated into human skin and protect against UV
465 radiation-induced cutaneous inflammation in association with reduced production
466 of pro-inflammatory eicosanoid 12-hydroxyeicosatetraenoic acid. *Br. J. Nutr.*
467 **2013**, *110* (5), 891–900.
- 468 (46) Stalmach, A.; Mullen, W.; Steiling, H.; Williamson, G.; Lean, M. E. J.; Crozier,
469 A. Absorption, metabolism, and excretion of green tea flavan-3-ols in humans
470 with an ileostomy. *Mol. Nutr. Food Res.* **2010**, *54* (3), 323–334.
- 471 (47) Del Rio, D.; Calani, L.; Scazzina, F.; Jechiu, L.; Cordero, C.; Brighenti, F.
472 Bioavailability of catechins from ready-to-drink tea. *Nutrition* **2010**, *26* (5), 528–
473 533.
- 474 (48) Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Rémésy, C.
475 Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97

- 476 bioavailability studies. *Am. J. Clin. Nutr.* **2005**, *81* (1 Suppl), 230S–242S.
- 477 (49) Chow, H.-H. S.; Hakim, I. A.; Vining, D. R.; Crowell, J. A.; Ranger-Moore, J.;
478 Chew, W. M.; Celaya, C. A.; Rodney, S. R.; Hara, Y.; Alberts, D. S. Effects of
479 dosing condition on the oral bioavailability of green tea catechins after single-
480 dose administration of Polyphenon E in healthy individuals. *Clin. Cancer Res.*
481 **2005**, *11* (12), 4627–4633.
- 482 (50) Stalmach, A.; Troufflard, S.; Serafini, M.; Crozier, A. Absorption, metabolism
483 and excretion of Choladi green tea flavan-3-ols by humans. *Mol. Nutr. Food Res.*
484 **2009**, *53 Suppl 1*, S44-53.
- 485 (51) Hutson, S. M.; Sweatt, A. J.; Lanoue, K. F. Branched-chain amino acid
486 metabolism: implications for establishing safe intakes. *J Nutr* **2005**, *135* (6
487 Suppl), 1557S–64S.
- 488 (52) Vázquez-Fresno, R.; Llorach, R.; Urpi-Sarda, M.; Khymenets, O.; Bullo, M.;
489 Corella, D.; Fito, M.; Martinez-Gonzalez, M. A.; Estruch, R.; Andres-Lacueva,
490 C. An NMR metabolomics approach reveals a combined-biomarkers model in a
491 wine interventional trial with validation in free-living individuals of the
492 PREDIMED study. *Metabolomics* **2015**, *11* (4), 797–806.
- 493 (53) Menni, C.; Fauman, E.; Erte, I.; Perry, J. R. B.; Kastenmuller, G.; Shin, S.-Y.;
494 Petersen, A.-K.; Hyde, C.; Psatha, M.; Ward, K. J.; et al. Biomarkers for Type 2
495 Diabetes and Impaired Fasting Glucose Using a Nontargeted Metabolomics
496 Approach. *Diabetes* **2013**, *62* (12), 4270–4276.
- 497 (54) Zhang, S.; Myracle, A.; Xiao, K.; Yan, P.; Ye, T.; Janle, E.; Raftery, D.
498 Metabolic Profiling of Green Tea Treatments in Zucker Diabetic Rats Using 1H
499 NMR. *J. Nutr. Food Sci.* **2013**, *3* (6).
- 500 (55) Most, J.; Goossens, G. H.; Jocken, J. W. E.; Blaak, E. E. Short-term

501 supplementation with a specific combination of dietary polyphenols increases
502 energy expenditure and alters substrate metabolism in overweight subjects. *Int. J.*
503 *Obes.* **2014**, *38* (5), 698–706.

504 (56) Kovacs, E. M. R.; Lejeune, M. P. G. M.; Nijs, I.; Westerterp-Plantenga, M. S.
505 Effects of green tea on weight maintenance after body-weight loss. *Br. J. Nutr.*
506 **2004**, *91* (3), 431.

507 (57) Dulloo, A. G.; Duret, C.; Rohrer, D.; Girardier, L.; Mensi, N.; Fathi, M.; Chantre,
508 P.; Vandermander, J. Efficacy of a green tea extract rich in catechin polyphenols
509 and caffeine in increasing 24-h energy expenditure and fat oxidation in humans.
510 *Am. J. Clin. Nutr.* **1999**, *70* (6), 1040–1045.

511 (58) Roowi, S.; Stalmach, A.; Mullen, W.; Lean, M. E. J.; Edwards, C. A.; Crozier, A.
512 Green tea flavan-3-ols: colonic degradation and urinary excretion of catabolites
513 by humans. *J. Agric. Food Chem.* **2010**, *58* (2), 1296–1304.

514 (59) Tomás-Barberán, F. A.; Selma, M. V.; Espín, J. C. Interactions of gut microbiota
515 with dietary polyphenols and consequences to human health. *Curr. Opin. Clin.*
516 *Nutr. Metab. Care* **2016**, *19* (6), 471–476.

517 (60) Kuriyama, S. The relation between green tea consumption and cardiovascular
518 disease as evidenced by epidemiological studies. *J. Nutr.* **2008**, *138* (8), 1548S–
519 1553S.

520 (61) Li, M.; Wang, B.; Zhang, M.; Rantalainen, M.; Wang, S.; Zhou, H.; Zhang, Y.;
521 Shen, J.; Pang, X.; Zhang, M.; et al. Symbiotic gut microbes modulate human
522 metabolic phenotypes. *Proc. Natl. Acad. Sci. U. S. A.* **2008**, *105* (6), 2117–2122.

523 (62) Calvani, R.; Miccheli, A.; Capuani, G.; Tomassini Miccheli, A.; Puccetti, C.;
524 Delfini, M.; Iaconelli, A.; Nanni, G.; Mingrone, G. Gut microbiome-derived
525 metabolites characterize a peculiar obese urinary metabotype. *Int. J. Obes.* **2010**,

526 34 (6), 1095–1098.

527 (63) Miquel, S.; Martín, R.; Rossi, O.; Bermúdez-Humarán, L.; Chatel, J.; Sokol, H.;

528 Thomas, M.; Wells, J.; Langella, P. Faecalibacterium prausnitzii and human

529 intestinal health. *Curr. Opin. Microbiol.* **2013**, *16* (3), 255–261.

530

531 **Table 1.** Tentative metabolites detected in urine of the participants in the present study.

Intervention type	Metabolite	δ (multiplicity)	HCT vs control	<i>P</i> value ¹	LR ²	
Acute	3-Methyl-2-oxovalerate	1.10 (d)	↑	4.72 x 10 ⁻⁵	7,11	
		0.89 (t)*		-	-	
	Theanine	3.80 (t)*	↑	-	-	
		3.18 (m)		5.67 x 10 ⁻³	20	
		2.04 (m)		2.77 x 10 ⁻⁶	1,2,15	
		1.12 (t)		3.00 x 10 ⁻⁵	5,10,24	
	Gallate	7.05 (s)	↑	2.11 x 10 ⁻²	-	
		7.01 (s)		7.55 x 10 ⁻³	21,29	
	EC	6.96 (m)	↑	5.22 x 10 ⁻³	19,22,25	
		6.16 (d)		2.18 x 10 ⁻⁵	4,27,36	
		6.12 (d)		1.46 x 10 ⁻³	12,33	
		4.36 (s)		2.52 x 10 ⁻²	-	
		2.94 (dd)		-	-	
		2.78 (dd)		-	-	
	EGC	6.50 (s)	↑	2.24 x 10 ⁻²	-	
		4.32 (m)*		-	-	
2.93 (m)		-		-		
2.81 (m)		-		-		
Sustained	2-Hydroxyisobutyrate	1.36 (s)	↓	3.60 x 10 ⁻²	-	
	Succinate	2.41 (s)	↑	1.81 x 10 ⁻²	-	
	Pyrogallol (sulfate)	7.05 (m)	↑	4.01 x 10 ⁻²	-	
6.59 (d)		3.81 x 10 ⁻³		-		
2 nd Acute	3-Methyl-2-oxovalerate	1.10 (d)	↑	3.51 x 10 ⁻⁴	6,24	
		0.89 (t)*		-	-	
	Theanine	3.80 (t)*	↑	-	-	
		3.18 (m)		-	-	
		2.04 (m)		8.14 x 10 ⁻⁶	1,5,39	
		1.12 (t)		4.47 x 10 ⁻³	21,44,55	
	Gallate	7.04 (d)	↑	5.94 x 10 ⁻³	26,70,93	
	EC	Succinate	2.41 (s)	↑	7.47 x 10 ⁻³	37
		7.01 (s)	↑	3.31 x 10 ⁻²	77,81	
		6.95 (m)		3.55 x 10 ⁻³	30,40,52	
		6.17 (d)		4.79 x 10 ⁻⁵	4,7,41	
		6.12 (d)		2.67 x 10 ⁻³	14,65	
4.36 (s)		3.88 x 10 ⁻²		-		
2.94 (dd)		1.86 x 10 ⁻²		51		
2.78 (dd)		1.79 x 10 ⁻²		49,53		
7.05 (m)	2.10 x 10 ⁻²	54,63,92				
Pyrogallol (sulfate)	6.59 (d)	↑	2.12 x 10 ⁻²	62,83		


532 ¹*P*-value of univariate statistical crossover model of differences. ²Loading rank of ML-

533 PLS-DA (when several LR values per signal, only the three lowest LR per signal were

534 reported). *Signals not considered because a strong overlapping. U: unknown, s: singlet,


535 d: doublet, t: triplet, dd: double doublet, m: multiplet, br s: broad singlet.

536




537
 538 **Figure 1.** Schematic representation of the randomized, placebo-controlled and
 539 crossover design of the study. HCT, high catechin tea.

540



541
 542 **Figure 2.** Box plots of urinary metabolites that were significantly different after high
 543 catechin tea (HCT) compared with control beverage in acute, sustained and repeated
 544 exposures. 3-M-2oxoalate: 3-methyl-2-oxoalerrate; EC, epicatechin; EGC,
 545 epigallocatechin.



546
 547 **Figure 3.** Main compounds found in the HCT urine of the participants in both acute and
 548 sustained interventions.